Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PiggyBac transposase is a DNA-cutting and -joining enzyme that recognizes terminal inverted repeats on the PiggyBac transposon and specifically integrates the transposon into genomic DNA at TTAA tetranucleotide target sites via a cut-and-paste mechanism. This process involves excision of the element from one genomic location and its precise insertion into a new location flanked by TTAA sequences, generating direct repeats at the integration site[1][3][5][9]. The PiggyBac system is widely used in genome engineering due to its high efficiency and preference for TTAA sites, although concerns remain about insertional mutagenesis and genomic instability in therapeutic contexts.
Enzyme inhibition (hypothetically, for drugs targeting the transposase), inhibition of DNA cleavage or integration (none clinically approved)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PiggyBac transposase (PB transposase).